Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Elite Pharmaceuticals (OTCQB: ELTP) has launched its generic methotrexate sodium 2.5 mg tablets. This medication is a dihydrofolate reductase inhibitor used to treat various conditions in adults and children, including acute lymphoblastic leukemia, rheumatoid arthritis, and severe psoriasis.
The product is marketed under the Elite Laboratories, Inc. label. According to IQVIA data, the total U.S. sales of methotrexate sodium 2.5 mg tablets were approximately $63 million for the 12 months ended May 2024. This launch represents Elite's entry into a significant market segment within the pharmaceutical industry.
Elite Pharmaceuticals (OTCQB: ELTP) ha lanciato le sue compresse generiche di metotrexato sodico da 2,5 mg. Questo medicinale è un inibitore della diidrofoolato reduttasi utilizzato per trattare varie condizioni negli adulti e nei bambini, tra cui leucemia linfoblastica acuta, artrite reumatoide e psoriasi severa.
Il prodotto è commercializzato con il marchio Elite Laboratories, Inc.. Secondo i dati IQVIA, le vendite totali negli Stati Uniti delle compresse di metotrexato sodico da 2,5 mg sono state di circa $63 milioni per i 12 mesi terminati a maggio 2024. Questo lancio rappresenta l'ingresso di Elite in un importante segmento di mercato all'interno dell'industria farmaceutica.
Elite Pharmaceuticals (OTCQB: ELTP) ha lanzado sus tabletas genéricas de metotrexato sódico de 2.5 mg. Este medicamento es un inhibidor de la dihidrofólico reductasa utilizado para tratar diversas condiciones en adultos y niños, incluyendo leucemia linfoblástica aguda, artritis reumatoide y psoriasis severa.
El producto se comercializa bajo la etiqueta de Elite Laboratories, Inc.. Según datos de IQVIA, las ventas totales en EE.UU. de tabletas de metotrexato sódico de 2.5 mg fueron aproximadamente $63 millones para los 12 meses terminados en mayo de 2024. Este lanzamiento representa la entrada de Elite en un segmento de mercado significativo dentro de la industria farmacéutica.
엘리트 제약 (OTCQB: ELTP)가 메토트렉세이트 나트륨 2.5mg 정제를 출시했습니다. 이 약물은 디하이드로폴레이트 환원효소 억제제로 성인과 아동의 여러 질환, 즉 급성 림프모구 Leukemia, 류마티스 관절염, 중증 건선 치료에 사용됩니다.
이 제품은 Elite Laboratories, Inc. 상표로 판매됩니다. IQVIA 데이터에 따르면, 미국 내 메토트렉세이트 나트륨 2.5mg 정제의 총 매출은 2024년 5월에 종료된 12개월 동안 약 $63백만에 달했습니다. 이번 출시는 제약 산업 내 중요한 시장 세그먼트로의 엘리트의 진입을 의미합니다.
Elite Pharmaceuticals (OTCQB: ELTP) a lancé ses comprimés génériques de méthotrexate sodique de 2,5 mg. Ce médicament est un inhibiteur de la dihydrofolate réductase utilisé pour traiter diverses conditions chez les adultes et les enfants, y compris leucémie lymphoblastique aiguë, arthrite rhumatoïde et psoriasis sévère.
Le produit est commercialisé sous l'étiquette Elite Laboratories, Inc.. Selon les données IQVIA, les ventes totales aux États-Unis des comprimés de méthotrexate sodique de 2,5 mg étaient d'environ 63 millions de dollars pour les 12 mois se terminant en mai 2024. Ce lancement représente l'entrée d'Elite dans un segment de marché significatif au sein de l'industrie pharmaceutique.
Elite Pharmaceuticals (OTCQB: ELTP) hat seine generischen Methotrexat-Natrium-Tabletten 2,5 mg auf den Markt gebracht. Dieses Medikament ist ein Dihydrofolat-Reduktase-Hemmer, das zur Behandlung verschiedener Erkrankungen bei Erwachsenen und Kindern eingesetzt wird, darunter akute lymphoblastische Leukämie, rheumatoide Arthritis und schwere Psoriasis.
Das Produkt wird unter dem Elite Laboratories, Inc. Label vermarktet. Laut IQVIA-Daten betrugen die gesamtumsätze in den USA für Methotrexat-Natrium-Tabletten 2,5 mg etwa 63 Millionen $ für die 12 Monate bis Mai 2024. Dieser Launch stellt den Eintritt von Elite in ein bedeutendes Marktsegment innerhalb der Pharmaindustrie dar.
- Launch of generic methotrexate sodium 2.5 mg tablets
- Entry into a market with approximately $63 million in annual U.S. sales
- None.
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic methotrexate sodium 2.5 mg tablets.
Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the:
- Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen, mycosis fungoides, relapsed or refractory non-Hodgkin's lymphoma as part of a metronomic combination regimen, rheumatoid arthritis and severe psoriasis
- Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) and acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen
This product is marketed and sold under the Elite Laboratories, Inc. label.
According to IQVIA, the total U.S. sales of methotrexate sodium 2.5 mg tablets were approximately
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
518-398-6222
Dianne@elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221158
FAQ
What new product has Elite Pharmaceuticals (ELTP) launched?
What is the market size for methotrexate sodium 2.5 mg tablets in the U.S.?
What are the medical uses for Elite Pharmaceuticals' (ELTP) new generic methotrexate sodium tablets?
Under which label is Elite Pharmaceuticals (ELTP) marketing its generic methotrexate sodium tablets?
